DOI: 10.1158/1078-0432.ccr-23-3087 ISSN: 1078-0432
In search of lost biomarker for immunotherapy in small-cell lung cancer
Christian Rolfo, Alessandro Russo- Cancer Research
- Oncology
Abstract
Chemo-immunotherapy is the current standard of care for extensive stage small-cell lung cancer (ES-SCLC), but predictive biomarkers are lacking. In a recent article, the authors report the predictive role of programed death ligand-1 (PD-L1) expression and tissue tumor mutational burden (TMB) on durvalumab ± tremelimumab + platinum-etoposide efficacy.